China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the official start of operations at its US subsidiary, Biocytogen Boston Corp., located in Waltham, Massachusetts. The new 3,400 sq.m. facility boasts advanced amenities and a convenient geographical location, marking a significant expansion as it is three times larger than the original facilities of Biocytogen Boston.
State-of-the-Art Facilities and Expansion Plans
The new site includes an SPF grade animal room equipped with 4,000 cages, as well as a cell culture and operation room, indicating the company’s commitment to advancing pre-clinical research capabilities. This expansion highlights Biocytogen’s investment in cutting-edge facilities to support its growing operations in North America and Europe.
Biocytogen Boston’s Growth and RenMab Platform
Biocytogen Boston, which specializes in providing high-quality pre-clinical models and research and development services, has experienced exponential business growth in the past five years. The company’s human antibody mice RenMab platform has been a key attraction for multiple companies, leading to a total of 50 deals as of June 30, 2023. This milestone underscores Biocytogen’s success in establishing partnerships and its contribution to the field of pre-clinical research and development.-Fineline Info & Tech
